Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
2012
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
2009
Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
2010
ESR1 Methylation: A Liquid Biopsy–Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment
2017
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
2012
Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes
2014
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
DNA methylation age of human tissues and cell types
2013 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
Genomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for Patients
2017
The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis
2018 Standout
Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent
2014 StandoutNobel
Pancreatic cancer genomics
2014
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Hepatocellular carcinoma
2016 Standout
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future
2016
Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis
2009
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
2009
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
2016 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Gold nanoparticles as novel agents for cancer therapy
2012
<p>The journey from gene knockout to clinical medicine: telotristat and sotagliflozin</p>
2019
Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
2016
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors
2016
Classification and functions of enteroendocrine cells of the lower gastrointestinal tract
2011
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor
2007
Management of Gallbladder Cancer
2010
Pancreatic Adenocarcinoma
2014 Standout
Gene therapy in pancreatic cancer
2014
Clinical trials with anti-angiogenic agents in hematological malignancies
2010
Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis
2011
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place
2008
Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
2012
Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways
2017 StandoutNobel
Genome-wide DNA methylation profiles in hepatocellular carcinoma
2012
Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis
2018 StandoutNobel
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration
2010
Malignant Gliomas in Adults
2008 Standout
Management of hypertension in angiogenesis inhibitor-treated patients
2009
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
2013
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
Adverse effects of anticancer agents that target the VEGF pathway
2009
Biomarkers of response and resistance to antiangiogenic therapy
2009
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives
2008
Gallbladder cancer: epidemiology and outcome
2014 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines
2009
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids
2010
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
2010 Standout
Maftools: efficient and comprehensive analysis of somatic variants in cancer
2018 Standout
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
2014
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition
2011
Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results
2013
Multidisciplinary approaches to intrahepatic cholangiocarcinoma
2013
Electrospinning and Electrospun Nanofibers: Methods, Materials, and Applications
2019 Standout
Management of ingested foreign bodies and food impactions
2011 Standout
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
2010
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
2009
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
2008
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
2012 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer
2023 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Combination therapy in combating cancer
2017 Standout
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
2011
Emerging Roles of Electrospun Nanofibers in Cancer Research
2017
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
2017 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Dialkylcarbamoyl chloride (DACC)-coated dressings in the management and prevention of wound infection: a systematic review
2017 StandoutNobel
Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies
2010
Genetics and biology of pancreatic ductal adenocarcinoma
2016
Chronic Inflammation and Cytokines in the Tumor Microenvironment
2014 Standout
Modifications in endoscopic practice for pediatric patients
2014
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
2010
Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound
2016
Works of Jan Harder being referenced
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
2012
Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
2006
Hepatitis C virus infection in intravenous drug users
2004
Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients
2011
KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy
2011
Treatment of unresectable cholangiocarcinoma
2012
Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients
2014
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
2009
Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver
2008
Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy
2012
EGFR overexpression induces activation of telomerase via PI3K/AKT‐mediated phosphorylation and transcriptional regulation through Hif1‐alpha in a cellular model of oral–esophageal carcinogenesis
2010
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
2007